humanized BCMA CAR-T

Humanized BCMA CAR-T refers to a class of autologous chimeric antigen receptor (CAR) T cell therapies engineered to target B-cell maturation antigen (BCMA), a protein highly expressed on malignant plasma cells in multiple myeloma. These therapies use a single-chain variable fragment (scFv) derived from a humanized antibody against BCMA to reduce immunogenicity compared to murine-based constructs. The process involves collecting the patient’s T cells, genetically modifying them ex vivo with a lentiviral vector encoding the anti-BCMA CAR construct (often including co-stimulatory domains such as CD28 or 4-1BB and CD3-zeta signaling domains), expanding them, and reinfusing them after lymphodepleting chemotherapy. Humanized BCMA CAR-T therapies have demonstrated high response rates in relapsed/refractory multiple myeloma and are being explored for other BCMA-positive cancers[1][4][5][7]. Notable examples include C-CAR088 and ARI2h.

Other names

humanized anti-BCMA CAR T cell therapyhumanized BCMA-CAR-T cells